4DMT shoots for a $75M IPO, its sec­ond at­tempt to go pub­lic with its gene ther­a­py vec­tor pro­grams

Just a few months af­ter with­draw­ing its IPO fil­ing, 4D Mol­e­c­u­lar Ther­a­peu­tics is seek­ing to go pub­lic once again.

The Emeryville, CA-based com­pa­ny sub­mit­ted a new S-1 on Tues­day, de­tail­ing plans for a $75 mil­lion raise as it aims for the sec­ond time to hit the Nas­daq. 4DMT had pre­vi­ous­ly sought a $100 mil­lion IPO back in Sep­tem­ber 2019, but with­drew the fil­ing in Ju­ly of this year af­ter com­plet­ing a $75 mil­lion Se­ries C in June.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.